The vascular side of COVID-19 disease
Position paper of the International Union of Angiology
Luca Costanzo, Giacomo Failla, Pier L. Antignani, Jawied Fareed, Yongquan Gu, Jan Pitha, Leonardo Aluigi, Thomas Karplus, Armando Mansilha
The SARS-CoV-2 infection (COVID-19) is causing an ongoing pandemic and potentially fatal disease. Development of coagulopathy with thrombotic complications such as deep vein thrombosis and pulmonary embolism are emerging as factors for progression to severe disease and death. Also, a markedly increased level of D-dimer, a protein product of fibrin degradation, has been associated to mortality. Furthermore, activation of immune response due to virus infection may led to uncontrolled severe inflammation with damage to host cells and induction of endotheliitis and cellular apoptosis and pyroptosis. The use of low molecular weight heparin in early stage of the disease could prevent vascular complications and reduce the progression to severe stage of the disease. Aim of this paper was to summarize current evidence about vascular involvement in COVID-19 disease and potential antithrombotic therapy.
Key words: COVID-19; Thrombosis; Blood coagulation disorders.
International Angiology 2020 December;39(6):445-51
Article first published online: September 7, 2020
© 2020 EDIZIONI MINERVA MEDICA